Effect of cisplatin on distortion product otoacoustic emissions in Japanese patients
- 5 April 2012
- journal article
- research article
- Published by Wiley in The Laryngoscope
- Vol. 122 (6) , 1392-1396
Abstract
Objectives/Hypothesis: Although it is well known that cisplatin is associated with ototoxicity, there is still a lack of knowledge concerning the ototoxicity of cisplatin, especially in Japanese head and neck cancer patients. The objectives of this study were to determine the incidence rate of cisplatin ototoxicity and to determine the threshold dose causing ototoxicity in the Japanese population.Study Design: Before‐and‐after study in a tertiary referral hospital.Methods: The distortion product otoacoustic emission (DPOAE) was measured 1 week after each administration of cisplatin in 44 Japanese head and neck cancer patients treated at Kyoto University Hospital. We determined the incidence and threshold dose of cisplatin ototoxicity according to DPOAE data.Results: The incidence of ototoxicity detected by DPOAE was 77.3%. The average DPOAE value was significantly lower in patients who received more than 200 mg/m2 cisplatin than the baseline DPOAE value. The threshold dose for cisplatin ototoxicity was lower in Japanese patients than in European patients.Conclusions: Our data suggest that Japanese patients are more susceptible to cisplatin‐induced ototoxicity. This is presumably caused by a genetic difference.Keywords
This publication has 27 references indexed in Scilit:
- Glutathione S-transferase M1 and T1 polymorphisms may predict adverse effects after therapy in children with medulloblastomaNeuro-Oncology, 2009
- Hydrogen protects auditory hair cells from free radicalsNeuroReport, 2009
- Factors Affecting Sensitivity of Distortion-Product Otoacoustic Emissions to Ototoxic Hearing LossEar & Hearing, 2008
- Identification of Genetic Variants Contributing to Cisplatin-Induced Cytotoxicity by Use of a Genomewide ApproachThe American Journal of Human Genetics, 2007
- Early Changes in Auditory Function As a Result of Platinum Chemotherapy: Use of Extended High-Frequency Audiometry and Evoked Distortion Product Otoacoustic EmissionsJournal of Clinical Oncology, 2007
- Characteristics and Risk Factors of Cisplatin-Induced Ototoxicity in Testicular Cancer Patients Detected by Distorsion Product Otoacoustic EmissionOncology, 2006
- Immediate and short-term reliability of distortion-product otoacoustic emissions: Confiabilidad inmediata y a corto plazo de las emisiones otoacústicas por productos de distorsiónInternational Journal of Audiology, 2003
- Third Place—Resident Clinical Science Award 1998: Effects of Cis‐Platinum Chemotherapy on Otoacoustic Emissions: The Development of an Objective Screening ProtocolOtolaryngology–Head and Neck Surgery, 1999
- Ototoxicity of low- and moderate-dose cisplatinCancer, 1985
- Ototoxicity of cis-diamminedichloroplatinum (II): Influence of dose, schedule and mode of administrationEuropean Journal of Cancer and Clinical Oncology, 1983